Canada - TSX Venture Exchange - TSX-V:MPH - CA58469E4085 - Common Stock
The current stock price of MPH.CA is 1.14 CAD. In the past month the price decreased by -8.8%. In the past year, price decreased by -2.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 517.64M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 401.93M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 170.33M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 79.24M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 26.14 | 50.54M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.36M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.73M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.59M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.96M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.19M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M |
Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.
MEDICURE INC
1250 Waverley Street
Winnipeg MANITOBA R3T 6C6 CA
CEO: Albert D. Friesen
Employees: 23
Phone: 12044877412
Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.
The current stock price of MPH.CA is 1.14 CAD. The price decreased by -5% in the last trading session.
MPH.CA does not pay a dividend.
MPH.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
MEDICURE INC (MPH.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.33).
You can find the ownership structure of MEDICURE INC (MPH.CA) on the Ownership tab.
ChartMill assigns a technical rating of 5 / 10 to MPH.CA. When comparing the yearly performance of all stocks, MPH.CA is a bad performer in the overall market: 76.43% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to MPH.CA. While MPH.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months MPH.CA reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -68.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.83% | ||
| ROE | -19.81% | ||
| Debt/Equity | 0.03 |